Candel Therapeutics Aims for Q4 2026 BLA Submission for Prostate Cancer Drug
Event summary
- Candel Therapeutics plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec in localized prostate cancer in Q4 2026.
- The company reported extended survival tail in a trial of aglatimagene in advanced non-small cell lung cancer (NSCLC) patients.
- Candel announced a commercial partnership with EVERSANA to support the potential U.S. launch of aglatimagene in localized prostate cancer.
- Cash and cash equivalents of $194.8 million as of March 31, 2026, are expected to fund operations into Q1 2028.
- The company plans to initiate a pivotal phase 3 clinical trial of aglatimagene in metastatic NSCLC in Q2 2026.
The big picture
Candel Therapeutics is advancing its lead clinical programs with a focus on preparing for the BLA submission of aglatimagene in prostate cancer. The company's strategic partnerships and strong cash position position it for a potential commercial launch in 2027. The broader biotechnology sector is watching closely as Candel navigates the regulatory and commercial landscape for its innovative immunotherapy candidates.
What we're watching
- Regulatory Approval
- Whether the FDA will approve the BLA submission for aglatimagene in Q4 2026.
- Clinical Trial Results
- The impact of extended follow-up data from the phase 3 trial of aglatimagene in prostate cancer.
- Commercial Strategy
- The effectiveness of the commercial partnership with EVERSANA in preparing for the U.S. launch of aglatimagene.
Related topics